Question 1

Who are the top researchers at QRx Pharma (United States)?

Accepted Answer

Ranked on the quality score, Patricia T. Richards lead among researchers whose main affiliation is QRx Pharma (United States).

Question 2

What are the most cited papers from QRx Pharma (United States)?

Accepted Answer

The most cited paper from QRx Pharma (United States) is "Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial" (Deepak L. Bhatt, Philippe Gabríel Steg, Eliot A. Brinton et al., 2017), with 183 citations. Next come "Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol" (127) and "High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk" (121).

Question 3

Which research topics does QRx Pharma (United States) publish most on?

Accepted Answer

By volume in 2022-now: Epilepsy research and treatment, RNA Interference and Gene Delivery, Virus-based gene therapy research and CRISPR and Genetic Engineering.

Question 4

Which fields of science does QRx Pharma (United States) work in?

Accepted Answer

In all years, 66% of research at QRx Pharma (United States) is in Health Sciences, 12% in Social Sciences. Its largest fields are Medicine (64%), Decision Sciences (10%), Biochemistry, Genetics and Molecular Biology (7%). It does 2.0× the world's share of Health Sciences.

Question 5

Is QRx Pharma (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 246% higher than in 2018-2021.